|
|
|
Priority Medicines Project
|
The purpose of the Priority Medicines for Europe and the World Project has been to study pharmaceutical
innovation from a public health perspective. The objective was to prepare a public-health-based medicines
development agenda for support by the European Union and to develop a systematic methodology for this that
can be replicated. For the purposes of this report, a public health perspective is one that is based on
principles of equity, evidence and efficiency. Within the context of identifying “pharmaceutical gaps”
which affect the citizens of Europe, special emphasis has been placed on identifying those research needs
which are also relevant for countries in economic transition and for developing countries. This
"commonality of interest" is an important bridging aspect of the Project between Europe and the world.
We can summarize the conclusions as follows:
- There is a commonality of interest for chronic diseases between Europe and the rest of the world
- Priorities can be set based on evidence, trends and projections and social solidarity
- Pharmaceutical gaps exist as a result of biological challenges and market failure
- Highest priorities are antibacterial resistance, influenza, cardiovascular disease and neglected diseases
- Pricing issues and barriers to innovation strongly affect the European industry
- The EU needs to find a way to support translational research for market failure pharmaceutical gaps
The report can be found here.
|
|
LATEST UPDATES
WHOCCPP
awarded funding for Interdisciplinary
Research and Training for Improving
Access to and Use of Medicines in China by Harvard
China Fund
Upcoming Courses
MedIC
Initiative Courses in Accra, Ghana, November 16-25, 2008
and Beijing, China in the Spring of 2009
|
